Want to see IN:NECLIFE full AI Analyst Report?
NECLIFE Stock Chart & Stats
₹10.30
-₹0.06(-0.58%)
At close: 4:00 PM EDT
₹10.30
-₹0.06(-0.58%)
Day’s Range― - ―
52-Week Range₹9.20 - ₹22.49
Previous CloseN/A
Volume4.76K
Average Volume (3M)34.32K
Market Cap
₹2.21B
Enterprise Value₹619.87
Total Cash (Recent Filing)₹1.25B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.41
Shares Outstanding194,260,970
10 Day Avg. Volume25,321
30 Day Avg. Volume34,323
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)97.56
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical Business ModelExposure to APIs, finished dosages and contract manufacturing gives Nectar multiple routes to serve pharmaceutical customers and diversify demand across products and channels, which can support recovery if one segment or market remains weak.
Historically Moderate LeverageHistorically moderate debt-to-equity and positive equity provide a capital structure that is less leveraged than a highly debt-funded model. This offers some financial flexibility, although current operating weakness limits the benefit.
Prior Cash GenerationOperating and free cash flow were positive in FY2022–FY2025, showing the business has previously converted operations into cash. That history provides evidence of potential cash-generation capacity, despite the severe FY2026 reversal.
Bears Say
Severe Revenue DisruptionA reported FY2026 revenue collapse to zero indicates a severe disruption in production, customer demand, or reporting continuity. This undermines visibility into the operating base and makes near-term recovery and sustainable scale difficult to assess.
Unstable ProfitabilityRepeated swings from near break-even results to meaningful and very large losses show weak earnings quality and limited margin resilience. Persistent unprofitability can reduce reinvestment capacity and make the business more dependent on external funding.
Acute Cash BurnVery large negative operating and free cash flow in FY2026 signals that operations are consuming liquidity rather than funding the business. If sustained, this can increase refinancing needs, constrain investment and heighten operational and funding risk.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹9.20 and its highest was ₹22.49 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.21B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 77 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.793 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of N/A. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 194,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of -₹0.793 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―